Rizatriptan Benzoate
Recommended · restricted NeurologyAuthority Required
Acute treatment of migraine attacks, with or without aura.
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Nov 2009Recommended · restricted
vs sumatriptan
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis performed; no ICER calculated by design.
The submission presented a cost-minimisation analysis based on the therapeutic claim that rizatriptan 5 mg (tablet/wafer) is non-inferior to sumatriptan 50 mg (tablet) in terms of effectiveness and safety and rizatriptan 10 mg (wafer/tablet) is non-inferior to sumatriptan 100 mg (tablet) in terms of effectiveness and safety. PSD · 2009
Decision context
PopulationPatients with migraine attacks (with or without aura) where attacks have usually failed to respond to analgesics.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2009 | Recommended · restricted | sumatriptan | — | RCT · pain-free at 2 hours |